Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00176_DB01142_nanopub.RAKSmpdYc1Kuk_2-Woh4prkIvOpv2E07vNGdfgceq4lko#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00176_DB01142 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB01142 label "DDI between Fluvoxamine and Doxepin - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB01142]" assertion.
- drugbank_resource:DB00176_DB01142 identifier "drugbank_resource:DB00176_DB01142" assertion.
- drugbank_resource:DB00176_DB01142 title "DDI between Fluvoxamine and Doxepin - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00176 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB01142 assertion.
- drugbank:DB01142 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB01142 assertion.